What is Amneal Pharmaceuticals, Inc.'s specialty — net revenue?

Amneal Pharmaceuticals, Inc. (AMRX) reported specialty — net revenue of $149.3M in Q2 2026.

How has Amneal Pharmaceuticals, Inc.'s specialty — net revenue changed year-over-year?

Amneal Pharmaceuticals, Inc.'s specialty — net revenue increased by 16.6% year-over-year, from $128.04M to $149.3M.

What does specialty — net revenue mean?

The total gross sales generated by the specialty pharmaceutical segment after accounting for returns, allowances, and rebates. This is a primary indicator of the segment's market demand and the commercial success of its branded pharmaceutical products.

Amneal Pharmaceuticals, Inc. (AMRX) Specialty — Net revenue

Screener

Other segment segments

Affordable Medicines

$489.91M—

AvKARE

$156.99M-3.7%

Similar metrics at other companies

IBPNet revenue, Installation — Net revenue

$710.7M-0.7%

MQPlatform services revenue, net — Net revenue

$156.23M+18.5%

VOther revenue — Net revenue

$1.5B+45.5%

VService revenue — Net revenue

$4.92B+13.7%

CVCODelivery, setup and other revenues — Net revenue

$23.21M-15.9%

AMDDatacenter — Net revenue

$10.25B+37.8%

Other financials

Income statement

See full

Revenue$796.2M+9.9%

Gross profit$334.5M+16.9%

Operating income$129.8M+16.5%

Net income$57.7M+157%

EPS (diluted)$0.18+157%

Balance sheet

See full

Cash & equivalents$127.6M+78.4%

Total debt$2.6B+18.0%

Total equity$33.0M+129%

Total assets$3.8B+10.3%

Cash flow

See full

Operating cash flow-$21.2M-125%

CapEx$30.7M+34.5%

Free cash flow-$51.9M-185%

Valuation

See full

Market cap$5.77B+129%

Enterprise value$8.21B+77.4%

P/E36.7×-711×

P/S1.9×+1.0×

Profitability

See full

Gross margin39.3%+1.7pp

Operating margin14.6%+1.4pp

Net margin5%+4.9pp

FCF margin4.1%-5.8pp

Returns & leverage

See full

Return on equity-52.8%-12.7pp

Debt / equity77.8×—

Current ratio2.2×+0.8×

Where this comes from

Reported directly by Amneal Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The source filing: Amneal Pharmaceuticals, Inc.’s 10-Q, filed August 6, 2026.

Filed: Aug 6, 2026, 5:19 PM EDT
Fiscal quarter: Q2 FY2026
Calendar quarter: Q2 2026
Accession: 0001723128-26-000031

Three Months Ended June 30, 2026	Affordable Medicines (1)	Specialty	Av KARE	Corporateand Other	Total Company
Net revenue	$489,913	$149,295	$156,989	—	$796,197
Cost of goods sold	282,684	48,265	130,740	—	461,689
Gross profit	207,229	101,030	26,249	—	334,508
Selling, general and administrative	42,367	40,095	16,913	49,347	148,722
Research and development	33,023	5,994	—	—	39,017
Intellectual property legal development expenses	2,002	85	—	—	2,087
Acquisition costs	—	—	—	7,600	7,600
Restructuring and other charges	—	—	—	554	554

Item 1. Financial Statements (Unaudited)

FAQ

What is Amneal Pharmaceuticals, Inc.'s specialty — net revenue?: Amneal Pharmaceuticals, Inc. (AMRX) reported specialty — net revenue of $149.3M in Q2 2026.
How has Amneal Pharmaceuticals, Inc.'s specialty — net revenue changed year-over-year?: Amneal Pharmaceuticals, Inc.'s specialty — net revenue increased by 16.6% year-over-year, from $128.04M to $149.3M.
What does specialty — net revenue mean?: The total gross sales generated by the specialty pharmaceutical segment after accounting for returns, allowances, and rebates. This is a primary indicator of the segment's market demand and the commercial success of its branded pharmaceutical products.